These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

413 related items for PubMed ID: 1815269

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Molecular epidemiology of high-level aminoglycoside-resistant enterococci isolated from patients in a university hospital in southern Italy.
    Zarrilli R, Tripodi MF, Di Popolo A, Fortunato R, Bagattini M, Crispino M, Florio A, Triassi M, Utili R.
    J Antimicrob Chemother; 2005 Nov; 56(5):827-35. PubMed ID: 16186168
    [Abstract] [Full Text] [Related]

  • 4. [Drug resistance of 100 clinical strains of Enterococcus spp].
    Sawicka-Grzelak A, Rokosz A, Luczak M.
    Med Dosw Mikrobiol; 1999 Nov; 51(3-4):239-47. PubMed ID: 10803253
    [Abstract] [Full Text] [Related]

  • 5. Susceptibility profile of Enterococcus faecalis isolated at the Lagos University Teaching Hospital, Nigeria.
    Iregbu KC, Ogunsola FT, Odugbemi TO.
    Niger Postgrad Med J; 2002 Sep; 9(3):125-8. PubMed ID: 12501265
    [Abstract] [Full Text] [Related]

  • 6. Prevalence of high level aminoglycoside and vancomycin resistance among enterococci in Turkey.
    Cirak MY, Sultan N.
    Acta Microbiol Pol; 1998 Sep; 47(3):267-73. PubMed ID: 9990710
    [Abstract] [Full Text] [Related]

  • 7. Antimicrobial resistance of enterococci in Turkey.
    Kaçmaz B, Aksoy A.
    Int J Antimicrob Agents; 2005 Jun; 25(6):535-8. PubMed ID: 15908184
    [Abstract] [Full Text] [Related]

  • 8. [Antibiotic susceptibility analysis of Enterococcus spp. isolated from urine].
    Rudy M, Nowakowska M, Wiechuła B, Zientara M, Radosz-Komoniewska H.
    Przegl Lek; 2004 Jun; 61(5):473-6. PubMed ID: 15515808
    [Abstract] [Full Text] [Related]

  • 9. In vitro antibacterial activities of eleven antibiotics against S. faecalis.
    Hartzen SH, Frimodt-Möller N, Andreasen JJ.
    APMIS; 1988 Jul; 96(7):584-8. PubMed ID: 3136781
    [Abstract] [Full Text] [Related]

  • 10. High-level resistance to aminoglycosides in enterococci; incidence and alternative active antibiotic combinations in vitro.
    Stefani S, D'Amico G, Mezzatesta ML, Lo Tauro R, Pellegrino MB, Nicoletti G.
    Drugs Exp Clin Res; 1990 Jul; 16(8):391-5. PubMed ID: 2129028
    [Abstract] [Full Text] [Related]

  • 11. Aminoglycoside-inactivating enzymes in clinical isolates of Streptococcus faecalis. An explanation for resistance to antibiotic synergism.
    Krogstad DJ, Korfhagen TR, Moellering RC, Wennersten C, Swartz MN.
    J Clin Invest; 1978 Aug; 62(2):480-6. PubMed ID: 97312
    [Abstract] [Full Text] [Related]

  • 12. Prevalence of vancomycin and high level aminoglycoside resistant enterococci among high-risk patients.
    Moaddab SR, Rafi A.
    Southeast Asian J Trop Med Public Health; 2003 Dec; 34(4):849-54. PubMed ID: 15115099
    [Abstract] [Full Text] [Related]

  • 13. [Enterococci as uropathogens. Frequency of isolation and sensitivity to antibacterial agents].
    Guirguitzova B, Chankova D, Zozikov B, Minkov N.
    Ann Urol (Paris); 1998 Dec; 32(1):15-9. PubMed ID: 9559070
    [Abstract] [Full Text] [Related]

  • 14. Time-kill and synergism studies of ceftobiprole against Enterococcus faecalis, including beta-lactamase-producing and vancomycin-resistant isolates.
    Arias CA, Singh KV, Panesso D, Murray BE.
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2043-7. PubMed ID: 17438057
    [Abstract] [Full Text] [Related]

  • 15. Antibiotic use in neonatal sepsis.
    Yurdakök M.
    Turk J Pediatr; 1998 Jun; 40(1):17-33. PubMed ID: 9722468
    [Abstract] [Full Text] [Related]

  • 16. [Enterococci: high level of resistance to aminoglycosides].
    del Valle-Ortiz O, Gallés C, Codina G, Cano A.
    Enferm Infecc Microbiol Clin; 1989 Dec; 7(10):535-41. PubMed ID: 2490431
    [Abstract] [Full Text] [Related]

  • 17. Insight into antimicrobial susceptibility and population structure of contemporary human Enterococcus faecalis isolates from Europe.
    Kuch A, Willems RJ, Werner G, Coque TM, Hammerum AM, Sundsfjord A, Klare I, Ruiz-Garbajosa P, Simonsen GS, van Luit-Asbroek M, Hryniewicz W, Sadowy E.
    J Antimicrob Chemother; 2012 Mar; 67(3):551-8. PubMed ID: 22207599
    [Abstract] [Full Text] [Related]

  • 18. Spread of an unusual penicillin- and imipenem-resistant but ampicillin-susceptible phenotype among Enterococcus faecalis clinical isolates.
    Metzidie E, Manolis EN, Pournaras S, Sofianou D, Tsakris A.
    J Antimicrob Chemother; 2006 Jan; 57(1):158-60. PubMed ID: 16308417
    [No Abstract] [Full Text] [Related]

  • 19. Early in vitro development of daptomycin non-susceptibility in high-level aminoglycoside-resistant Enterococcus faecalis predicts the efficacy of the combination of high-dose daptomycin plus ampicillin in an in vivo model of experimental endocarditis.
    Pericàs JM, García-de-la-Mària C, Brunet M, Armero Y, García-González J, Casals G, Almela M, Quintana E, Falces C, Ninot S, Fuster D, Llopis J, Marco F, Moreno A, Miró JM, Hospital Clinic Endocarditis Study Group.
    J Antimicrob Chemother; 2017 Jun 01; 72(6):1714-1722. PubMed ID: 28204495
    [Abstract] [Full Text] [Related]

  • 20. High-level aminoglycoside resistance in enterococci.
    Gutiérrez J, Hoyos A, Piedrola G.
    Ann Biol Clin (Paris); 1992 Jun 01; 50(10-11):671-4. PubMed ID: 1306949
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.